Aridis Pharmaceuticals Stock Alpha and Beta Analysis
| ARDS Stock | USD 0.0002 0 91.30% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Aridis Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Aridis Pharmaceuticals over a specified time horizon. Remember, high Aridis Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Aridis Pharmaceuticals' market risk premium analysis include:
Beta (64.77) | Alpha 112.46 | Risk 313.68 | Sharpe Ratio 0.33 | Expected Return 104.01 |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Aridis |
Aridis Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Aridis Pharmaceuticals market risk premium is the additional return an investor will receive from holding Aridis Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aridis Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Aridis Pharmaceuticals' performance over market.| α | 112.46 | β | -64.77 |
Aridis Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Aridis Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Aridis Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Aridis Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Aridis Pharmaceuticals pink sheet reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aridis Pharmaceuticals shares will generate the highest return on investment. By understating and applying Aridis Pharmaceuticals pink sheet market price indicators, traders can identify Aridis Pharmaceuticals position entry and exit signals to maximize returns.
Aridis Pharmaceuticals Return and Market Media
The median price of Aridis Pharmaceuticals for the period between Thu, Oct 2, 2025 and Wed, Dec 31, 2025 is 2.0E-4 with a coefficient of variation of 103.65. The daily time series for the period is distributed with a sample standard deviation of 0.0, arithmetic mean of 0.0, and mean deviation of 0.0. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
About Aridis Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Aridis or other pink sheets. Alpha measures the amount that position in Aridis Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Aridis Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Aridis Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aridis Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Aridis Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Aridis Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Aridis Pharmaceuticals' management manipulating its earnings.
| 15th of August 2023 Upcoming Quarterly Report | View | |
| 20th of November 2023 Next Financial Report | View | |
| 30th of June 2023 Next Fiscal Quarter End | View | |
| 27th of May 2024 Next Fiscal Year End | View | |
| 31st of March 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Aridis Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Aridis Pink Sheet Analysis
When running Aridis Pharmaceuticals' price analysis, check to measure Aridis Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aridis Pharmaceuticals is operating at the current time. Most of Aridis Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aridis Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aridis Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aridis Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.